Bolt Biotherapeutics, Inc. BOLT
5.06 USD -0.04 (-0.78%)
Regular-session close
5.06 0.00 0.00%
After hours · Nov 19, 4:00 PM ET
5.06 Day range 5.29
3.10 52-week range 7.78
- YTD
- -7.50%
- 1 year
- +8.12%
News
benzinga.com Bolt Biotherapeutics Q3 EPS $(2.25) Beats $(3.69) Estimate Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(2.25) per share which beat the analyst consensus estimate of $(3.69) by 38.86 percent. This is a 39.52 percent increase over losses…
globenewswire.com Bolt Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update Completed acquisition of Prana Therapies and $120 million concurrent private placement financing, establishing PRA-216 and the INSPIRE-built pipeline as Bolt's primary development focus Initiated…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Bolt Biotherapeutics (NASDAQ:BOLT) shares moved upwards by 58.8% to $6.65 during Friday's regular session. The market value of their outstanding shares is at $7.9 million. Lucid Diagnostics…benzinga.com Bolt’s Acquisition Positions It To Advance Prana’s Inspire Multispecific Antibody Pipeline; Phase 2 PRA-216 Readouts Expected Starting Q2 2027 Prana’s Pipeline Overview and Development MilestonesPrana’s focus is to develop the next generation of half-life-extended multispecific antibodies designed to deliver best-in-disease therapies. The…
benzinga.com Bolt Biotherapeutics Secures $120M Private Placement, With Potential Additional $60M From Warrant Exercise To Fund Operations Into 2028 Concurrent with the acquisition, Bolt entered into a definitive agreement for a private placement financing to raise $120 million in gross proceeds, for the purchase of 13,995.311 shares of Series D…
benzinga.com Bolt Biotherapeutics Acquires Prana Therapies In Sign-And-Close Reverse Merger, Shifts Focus To Multispecific Antibody Pipeline; Prana Holders to Own 51.7% of Combined Company, Backed by Up To $180M Financing Transactions position the company to advance Prana’s pipeline of next-generation, half-life-extended multispecific antibodies enabled by its proprietary INSPIRE platform PRA-216 is a novel…
